CN100376557C - 作为神经肽y受体的配体的喹啉衍生物 - Google Patents

作为神经肽y受体的配体的喹啉衍生物 Download PDF

Info

Publication number
CN100376557C
CN100376557C CNB028104013A CN02810401A CN100376557C CN 100376557 C CN100376557 C CN 100376557C CN B028104013 A CNB028104013 A CN B028104013A CN 02810401 A CN02810401 A CN 02810401A CN 100376557 C CN100376557 C CN 100376557C
Authority
CN
China
Prior art keywords
methyl
quinoline
alkyl
pyrrolidin
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028104013A
Other languages
English (en)
Chinese (zh)
Other versions
CN1522249A (zh
Inventor
维尔纳·米勒
维尔纳·奈德哈特
菲利普·普夫利格
让-马克·普朗谢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Hoffmann La Roche Inc
Original Assignee
F Hoffmann La Roche AG
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Hoffmann La Roche Inc filed Critical F Hoffmann La Roche AG
Publication of CN1522249A publication Critical patent/CN1522249A/zh
Application granted granted Critical
Publication of CN100376557C publication Critical patent/CN100376557C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028104013A 2001-05-21 2002-05-08 作为神经肽y受体的配体的喹啉衍生物 Expired - Fee Related CN100376557C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112370 2001-05-21
EP01112370.0 2001-05-21

Publications (2)

Publication Number Publication Date
CN1522249A CN1522249A (zh) 2004-08-18
CN100376557C true CN100376557C (zh) 2008-03-26

Family

ID=8177497

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028104013A Expired - Fee Related CN100376557C (zh) 2001-05-21 2002-05-08 作为神经肽y受体的配体的喹啉衍生物

Country Status (19)

Country Link
US (2) US6818767B2 (enExample)
EP (1) EP1395564B1 (enExample)
JP (1) JP3715280B2 (enExample)
KR (1) KR100621287B1 (enExample)
CN (1) CN100376557C (enExample)
AR (1) AR035979A1 (enExample)
AT (1) ATE387428T1 (enExample)
AU (1) AU2002338896B2 (enExample)
BR (1) BR0209957A (enExample)
CA (1) CA2446324A1 (enExample)
DE (1) DE60225274T2 (enExample)
ES (1) ES2300478T3 (enExample)
GT (1) GT200200090A (enExample)
MX (1) MXPA03010565A (enExample)
PA (1) PA8545301A1 (enExample)
PE (1) PE20021155A1 (enExample)
UY (1) UY27300A1 (enExample)
WO (1) WO2002094789A1 (enExample)
ZA (1) ZA200308783B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
AU2002352878B2 (en) * 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
PL372295A1 (en) * 2002-02-04 2005-07-11 F.Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CA2489251A1 (en) 2002-07-05 2004-01-15 F. Hoffmann-La Roche Ag Quinazoline derivatives
AU2003253364B2 (en) 2002-08-07 2007-06-07 F. Hoffmann-La Roche Ag Thiazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MXPA05009722A (es) * 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
CA2545340A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
EP1892241B1 (en) 2005-05-30 2016-03-30 Msd K.K. Novel piperidine derivative
EP1916239A4 (en) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd PYRIDOLVERBINDUNG
US7875633B2 (en) 2005-08-24 2011-01-25 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
RU2428423C2 (ru) 2005-11-10 2011-09-10 Баниу Фармасьютикал Ко., Лтд. Азазамещенные спиропроизводные
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
WO2008141077A1 (en) * 2007-05-10 2008-11-20 Janssen Pharmaceutica N.V. Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives
US8759348B2 (en) * 2007-05-17 2014-06-24 Helperby Therapeutics Limited Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
WO2008150940A1 (en) * 2007-06-01 2008-12-11 E. I. Du Pont De Nemours And Company Chrysenes for green luminescent applications
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
SI2220076T1 (sl) * 2007-11-15 2012-05-31 Gilead Sciences Inc Inhibitorji replikacije virusa humane imunske pomankljivosti
US8354429B2 (en) 2007-11-16 2013-01-15 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
CA2717384A1 (en) 2008-03-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
ES3002968T3 (en) 2017-07-14 2025-03-10 Innate Tumor Immunity Inc Nlrp3 modulators

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB991838A (en) * 1962-06-14 1965-05-12 Rhone Poulenc Sa Quinoline derivatives
US3272824A (en) * 1962-12-06 1966-09-13 Norwich Pharma Co 4-amino-6, 7-di(lower) alkoxyquinolines
US3812127A (en) * 1966-10-31 1974-05-21 Pfizer 4-(quinolin-4-yl)piperazine-1-carboxylic acid esters
US4035367A (en) * 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
CN1208404A (zh) * 1996-10-01 1999-02-17 协和发酵工业株式会社 含氮杂环化合物
CN1444563A (zh) * 2000-09-06 2003-09-24 霍夫曼-拉罗奇有限公司 喹啉和喹唑啉衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
AU641215B2 (en) 1990-02-13 1993-09-16 Merrell Dow Pharmaceuticals Inc. Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
WO2001034764A2 (en) * 1999-11-08 2001-05-17 Cytion S.A. Apparatus and methods for positioning and analyzing biological membranous objects

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB991838A (en) * 1962-06-14 1965-05-12 Rhone Poulenc Sa Quinoline derivatives
US3272824A (en) * 1962-12-06 1966-09-13 Norwich Pharma Co 4-amino-6, 7-di(lower) alkoxyquinolines
US3812127A (en) * 1966-10-31 1974-05-21 Pfizer 4-(quinolin-4-yl)piperazine-1-carboxylic acid esters
US4035367A (en) * 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
CN1208404A (zh) * 1996-10-01 1999-02-17 协和发酵工业株式会社 含氮杂环化合物
CN1444563A (zh) * 2000-09-06 2003-09-24 霍夫曼-拉罗奇有限公司 喹啉和喹唑啉衍生物

Also Published As

Publication number Publication date
AR035979A1 (es) 2004-07-28
PE20021155A1 (es) 2002-12-17
JP3715280B2 (ja) 2005-11-09
AU2002338896B2 (en) 2006-04-27
ZA200308783B (en) 2005-02-11
EP1395564B1 (en) 2008-02-27
US6818767B2 (en) 2004-11-16
JP2004536066A (ja) 2004-12-02
UY27300A1 (es) 2002-11-29
WO2002094789A1 (en) 2002-11-28
CN1522249A (zh) 2004-08-18
KR100621287B1 (ko) 2006-09-13
ES2300478T3 (es) 2008-06-16
US20020198194A1 (en) 2002-12-26
US20050049413A1 (en) 2005-03-03
EP1395564A1 (en) 2004-03-10
CA2446324A1 (en) 2002-11-28
PA8545301A1 (es) 2003-01-24
DE60225274D1 (de) 2008-04-10
BR0209957A (pt) 2004-03-30
MXPA03010565A (es) 2004-03-02
GT200200090A (es) 2003-06-19
KR20030096416A (ko) 2003-12-24
ATE387428T1 (de) 2008-03-15
DE60225274T2 (de) 2009-03-26

Similar Documents

Publication Publication Date Title
JP3715280B2 (ja) ニューロペプチドyレセプターのリガンドとしてのキノリン誘導体
RU2298002C2 (ru) Производные хинолина в качестве антагонистов npy
KR100605140B1 (ko) 심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법
US7265125B2 (en) Neuropeptide Y antagonists
JP2786480B2 (ja) 1―インドリルアルキル―4―(置換ピリジニル)ピペラジン
JP4387103B2 (ja) セロトニン5ht−2レセプターのアゴニストまたはアンタゴニストとしてのピペラジニルピラジン化合物
JP3193718B2 (ja) 中枢神経系剤としての1,3−置換シクロアルケンおよびシクロアルカン
JP2000512296A (ja) セロトニン再取込み阻害
JP2002535331A (ja) 新規血管形成阻害薬
JPH11502816A (ja) 5−置換−3−(1,2,3,6−テトラヒドロピリジン−4−イル)−および3−(ピペリジン−4−イル)−1h−インドール類:新規5−ht▲下1f▼アゴニスト
KR20020038959A (ko) 티로신 키나제 억제제
JP2009541461A (ja) 5−ht6モジュレーターとしてのインドール
JPH09508137A (ja) セロトニンアゴニストおよびアンタゴニストとしての4−インドール誘導体
KR20010085555A (ko) 아드레날린 알파1비 수용체 길항약
JP2002515486A (ja) 掻痒性皮膚病の治療用の新規4−フェニルピペリジン
TW200811158A (en) Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application
TWI454461B (zh) 作為nk3拮抗劑之異喹啉酮衍生物
TW201625581A (zh) 側氧雜環衍生物
CZ289998B6 (cs) Léčivo proti nachlazení nebo alergické rinitidě
JP2005514389A (ja) タキキニンのアンタゴニストとしてのラクタム
WO1994021627A1 (en) Indole derivatives as dopamine d4 antagonists
KR101923365B1 (ko) Crth2 길항제로서의 피라졸 화합물들
CN102971310B (zh) (3-甲基-吡咯烷-3-基)甲基-吡啶基醚衍生物及它们作为nk-3受体拮抗剂的用途
JPWO2009041559A1 (ja) インダゾールアクリル酸アミド化合物
CN102656157B (zh) 作为nk-3受体拮抗剂的吡咯烷衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080326